Autologous	B:C0040736
transplant	I:C0040736
vs	O
oral	O
chemotherapy	I:C0419073
and	O
lenalidomide	O
in	O
newly	O
diagnosed	O
young	O
myeloma	O
patients	O
:	O
a	O
pooled	O
analysis	I:C0242481
.	O

Autologous	O
transplant	I:C0040736
vs	O
oral	B:C0419073
chemotherapy	I:C0419073
and	O
lenalidomide	O
in	O
newly	O
diagnosed	O
young	O
myeloma	O
patients	O
:	O
a	O
pooled	O
analysis	I:C0242481
.	O

Autologous	O
transplant	I:C0040736
vs	O
oral	O
chemotherapy	I:C0419073
and	O
lenalidomide	B:C1144149
in	O
newly	O
diagnosed	O
young	O
myeloma	O
patients	O
:	O
a	O
pooled	O
analysis	I:C0242481
.	O

Autologous	O
transplant	I:C0040736
vs	O
oral	O
chemotherapy	I:C0419073
and	O
lenalidomide	O
in	O
newly	O
diagnosed	O
young	O
myeloma	B:C0026764
patients	O
:	O
a	O
pooled	O
analysis	I:C0242481
.	O

Autologous	O
transplant	I:C0040736
vs	O
oral	O
chemotherapy	I:C0419073
and	O
lenalidomide	O
in	O
newly	O
diagnosed	O
young	O
myeloma	O
patients	O
:	O
a	O
pooled	B:C0242481
analysis	I:C0242481
.	O

In	O
newly	O
diagnosed	O
myeloma	B:C0026764
patients	O
,	O
upfront	O
autologous	I:C0040736
transplant	I:C0040736
(	O
ASCT	O
)	O
prolongs	O
progression	O
-	O
free	O
survival	O
1	O
(	O
PFS1	O
)	O
compared	O
with	O
chemotherapy	O
plus	O
lenalidomide	O
(	O
CC	O
+	O
R	O
)	O
.	O

In	O
newly	O
diagnosed	O
myeloma	O
patients	O
,	O
upfront	B:C0040736
autologous	I:C0040736
transplant	I:C0040736
(	O
ASCT	O
)	O
prolongs	O
progression	O
-	O
free	O
survival	O
1	O
(	O
PFS1	O
)	O
compared	O
with	O
chemotherapy	O
plus	O
lenalidomide	O
(	O
CC	O
+	O
R	O
)	O
.	O

In	O
newly	O
diagnosed	O
myeloma	O
patients	O
,	O
upfront	O
autologous	I:C0040736
transplant	I:C0040736
(	O
ASCT	B:C0040736
)	O
prolongs	O
progression	O
-	O
free	O
survival	O
1	O
(	O
PFS1	O
)	O
compared	O
with	O
chemotherapy	O
plus	O
lenalidomide	O
(	O
CC	O
+	O
R	O
)	O
.	O

In	O
newly	O
diagnosed	O
myeloma	O
patients	O
,	O
upfront	O
autologous	I:C0040736
transplant	I:C0040736
(	O
ASCT	O
)	O
prolongs	O
progression	O
-	O
free	O
survival	O
1	O
(	O
PFS1	O
)	O
compared	O
with	O
chemotherapy	B:C3665472
plus	O
lenalidomide	O
(	O
CC	O
+	O
R	O
)	O
.	O

In	O
newly	O
diagnosed	O
myeloma	O
patients	O
,	O
upfront	O
autologous	I:C0040736
transplant	I:C0040736
(	O
ASCT	O
)	O
prolongs	O
progression	O
-	O
free	O
survival	O
1	O
(	O
PFS1	O
)	O
compared	O
with	O
chemotherapy	O
plus	O
lenalidomide	B:C1144149
(	O
CC	O
+	O
R	O
)	O
.	O

In	O
newly	O
diagnosed	O
myeloma	O
patients	O
,	O
upfront	O
autologous	I:C0040736
transplant	I:C0040736
(	O
ASCT	O
)	O
prolongs	O
progression	O
-	O
free	O
survival	O
1	O
(	O
PFS1	O
)	O
compared	O
with	O
chemotherapy	O
plus	O
lenalidomide	O
(	O
CC	B:C3665472
+	O
R	O
)	O
.	O

In	O
newly	O
diagnosed	O
myeloma	O
patients	O
,	O
upfront	O
autologous	I:C0040736
transplant	I:C0040736
(	O
ASCT	O
)	O
prolongs	O
progression	O
-	O
free	O
survival	O
1	O
(	O
PFS1	O
)	O
compared	O
with	O
chemotherapy	O
plus	O
lenalidomide	O
(	O
CC	O
+	O
R	B:C1144149
)	O
.	O

Salvage	B:C0085405
ASCT	O
at	O
first	O
relapse	O
may	O
still	O
effectively	O
rescue	O
patients	O
who	O
did	O
not	O
receive	O
upfront	O
ASCT	I:C0040736
.	O

Salvage	O
ASCT	B:C0040736
at	O
first	O
relapse	O
may	O
still	O
effectively	O
rescue	O
patients	O
who	O
did	O
not	O
receive	O
upfront	O
ASCT	I:C0040736
.	O

Salvage	O
ASCT	O
at	O
first	O
relapse	O
may	O
still	O
effectively	O
rescue	O
patients	O
who	O
did	O
not	O
receive	O
upfront	B:C0040736
ASCT	I:C0040736
.	O

To	O
evaluate	O
the	O
long	O
-	O
term	O
benefit	O
of	O
upfront	B:C0040736
ASCT	I:C0040736
vs	O
CC	O
+	O
R	O
and	O
the	O
impact	O
of	O
salvage	O
ASCT	O
in	O
patients	O
who	O
received	O
upfront	O
CC	O
+	O
R	O
,	O
we	O
conducted	O
a	O
pooled	O
analysis	O
of	O
2	O
phase	O
III	O
trials	O
(	O
RV	O
-	I:C0242481
MM	I:C0242481
-	I:C0242481
209	I:C0242481
and	O
EMN	O
-	I:C0242481
441	I:C0242481
)	O
.	O

To	O
evaluate	O
the	O
long	O
-	O
term	O
benefit	O
of	O
upfront	O
ASCT	I:C0040736
vs	O
CC	B:C3665472
+	O
R	O
and	O
the	O
impact	O
of	O
salvage	O
ASCT	O
in	O
patients	O
who	O
received	O
upfront	O
CC	O
+	O
R	O
,	O
we	O
conducted	O
a	O
pooled	O
analysis	O
of	O
2	O
phase	O
III	O
trials	O
(	O
RV	O
-	I:C0242481
MM	I:C0242481
-	I:C0242481
209	I:C0242481
and	O
EMN	O
-	I:C0242481
441	I:C0242481
)	O
.	O

To	O
evaluate	O
the	O
long	O
-	O
term	O
benefit	O
of	O
upfront	O
ASCT	I:C0040736
vs	O
CC	O
+	O
R	B:C1144149
and	O
the	O
impact	O
of	O
salvage	O
ASCT	O
in	O
patients	O
who	O
received	O
upfront	O
CC	O
+	O
R	O
,	O
we	O
conducted	O
a	O
pooled	O
analysis	O
of	O
2	O
phase	O
III	O
trials	O
(	O
RV	O
-	I:C0242481
MM	I:C0242481
-	I:C0242481
209	I:C0242481
and	O
EMN	O
-	I:C0242481
441	I:C0242481
)	O
.	O

To	O
evaluate	O
the	O
long	O
-	O
term	O
benefit	O
of	O
upfront	O
ASCT	I:C0040736
vs	O
CC	O
+	O
R	O
and	O
the	O
impact	O
of	O
salvage	B:C0085405
ASCT	O
in	O
patients	O
who	O
received	O
upfront	O
CC	O
+	O
R	O
,	O
we	O
conducted	O
a	O
pooled	O
analysis	O
of	O
2	O
phase	O
III	O
trials	O
(	O
RV	O
-	I:C0242481
MM	I:C0242481
-	I:C0242481
209	I:C0242481
and	O
EMN	O
-	I:C0242481
441	I:C0242481
)	O
.	O

To	O
evaluate	O
the	O
long	O
-	O
term	O
benefit	O
of	O
upfront	O
ASCT	I:C0040736
vs	O
CC	O
+	O
R	O
and	O
the	O
impact	O
of	O
salvage	O
ASCT	B:C0040736
in	O
patients	O
who	O
received	O
upfront	O
CC	O
+	O
R	O
,	O
we	O
conducted	O
a	O
pooled	O
analysis	O
of	O
2	O
phase	O
III	O
trials	O
(	O
RV	O
-	I:C0242481
MM	I:C0242481
-	I:C0242481
209	I:C0242481
and	O
EMN	O
-	I:C0242481
441	I:C0242481
)	O
.	O

To	O
evaluate	O
the	O
long	O
-	O
term	O
benefit	O
of	O
upfront	O
ASCT	I:C0040736
vs	O
CC	O
+	O
R	O
and	O
the	O
impact	O
of	O
salvage	O
ASCT	O
in	O
patients	O
who	O
received	O
upfront	O
CC	B:C3665472
+	O
R	O
,	O
we	O
conducted	O
a	O
pooled	O
analysis	O
of	O
2	O
phase	O
III	O
trials	O
(	O
RV	O
-	I:C0242481
MM	I:C0242481
-	I:C0242481
209	I:C0242481
and	O
EMN	O
-	I:C0242481
441	I:C0242481
)	O
.	O

To	O
evaluate	O
the	O
long	O
-	O
term	O
benefit	O
of	O
upfront	O
ASCT	I:C0040736
vs	O
CC	O
+	O
R	O
and	O
the	O
impact	O
of	O
salvage	O
ASCT	O
in	O
patients	O
who	O
received	O
upfront	O
CC	O
+	O
R	B:C1144149
,	O
we	O
conducted	O
a	O
pooled	O
analysis	O
of	O
2	O
phase	O
III	O
trials	O
(	O
RV	O
-	I:C0242481
MM	I:C0242481
-	I:C0242481
209	I:C0242481
and	O
EMN	O
-	I:C0242481
441	I:C0242481
)	O
.	O

To	O
evaluate	O
the	O
long	O
-	O
term	O
benefit	O
of	O
upfront	O
ASCT	I:C0040736
vs	O
CC	O
+	O
R	O
and	O
the	O
impact	O
of	O
salvage	O
ASCT	O
in	O
patients	O
who	O
received	O
upfront	O
CC	O
+	O
R	O
,	O
we	O
conducted	O
a	O
pooled	O
analysis	B:C0936012
of	O
2	O
phase	O
III	O
trials	O
(	O
RV	O
-	I:C0242481
MM	I:C0242481
-	I:C0242481
209	I:C0242481
and	O
EMN	O
-	I:C0242481
441	I:C0242481
)	O
.	O

To	O
evaluate	O
the	O
long	O
-	O
term	O
benefit	O
of	O
upfront	O
ASCT	I:C0040736
vs	O
CC	O
+	O
R	O
and	O
the	O
impact	O
of	O
salvage	O
ASCT	O
in	O
patients	O
who	O
received	O
upfront	O
CC	O
+	O
R	O
,	O
we	O
conducted	O
a	O
pooled	O
analysis	O
of	O
2	O
phase	O
III	O
trials	B:C0008976
(	O
RV	O
-	I:C0242481
MM	I:C0242481
-	I:C0242481
209	I:C0242481
and	O
EMN	O
-	I:C0242481
441	I:C0242481
)	O
.	O

To	O
evaluate	O
the	O
long	O
-	O
term	O
benefit	O
of	O
upfront	O
ASCT	I:C0040736
vs	O
CC	O
+	O
R	O
and	O
the	O
impact	O
of	O
salvage	O
ASCT	O
in	O
patients	O
who	O
received	O
upfront	O
CC	O
+	O
R	O
,	O
we	O
conducted	O
a	O
pooled	O
analysis	O
of	O
2	O
phase	O
III	O
trials	O
(	O
RV	B:C0242481
-	I:C0242481
MM	I:C0242481
-	I:C0242481
209	I:C0242481
and	O
EMN	O
-	I:C0242481
441	I:C0242481
)	O
.	O

To	O
evaluate	O
the	O
long	O
-	O
term	O
benefit	O
of	O
upfront	O
ASCT	I:C0040736
vs	O
CC	O
+	O
R	O
and	O
the	O
impact	O
of	O
salvage	O
ASCT	O
in	O
patients	O
who	O
received	O
upfront	O
CC	O
+	O
R	O
,	O
we	O
conducted	O
a	O
pooled	O
analysis	O
of	O
2	O
phase	O
III	O
trials	O
(	O
RV	O
-	I:C0242481
MM	I:C0242481
-	I:C0242481
209	I:C0242481
and	O
EMN	B:C0242481
-	I:C0242481
441	I:C0242481
)	O
.	O

A	O
total	O
of	O
268	O
patients	O
were	O
randomized	B:C0206034
to	O
2	O
courses	O
of	O
melphalan	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
ASCT	O
(	O
MEL	O
200	O
-	O
ASCT	O
)	O
and	O
261	O
to	O
CC	O
+	O
R.	O
Median	O
follow	O
-	I:C1522577
up	I:C1522577
was	O
46	O
months	O
.	O

A	O
total	O
of	O
268	O
patients	O
were	O
randomized	O
to	O
2	O
courses	O
of	O
melphalan	B:C0025241
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
ASCT	O
(	O
MEL	O
200	O
-	O
ASCT	O
)	O
and	O
261	O
to	O
CC	O
+	O
R.	O
Median	O
follow	O
-	I:C1522577
up	I:C1522577
was	O
46	O
months	O
.	O

A	O
total	O
of	O
268	O
patients	O
were	O
randomized	O
to	O
2	O
courses	O
of	O
melphalan	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
ASCT	B:C0040736
(	O
MEL	O
200	O
-	O
ASCT	O
)	O
and	O
261	O
to	O
CC	O
+	O
R.	O
Median	O
follow	O
-	I:C1522577
up	I:C1522577
was	O
46	O
months	O
.	O

A	O
total	O
of	O
268	O
patients	O
were	O
randomized	O
to	O
2	O
courses	O
of	O
melphalan	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
ASCT	O
(	O
MEL	B:C0025241
200	O
-	O
ASCT	O
)	O
and	O
261	O
to	O
CC	O
+	O
R.	O
Median	O
follow	O
-	I:C1522577
up	I:C1522577
was	O
46	O
months	O
.	O

A	O
total	O
of	O
268	O
patients	O
were	O
randomized	O
to	O
2	O
courses	O
of	O
melphalan	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
ASCT	O
(	O
MEL	O
200	O
-	O
ASCT	B:C0040736
)	O
and	O
261	O
to	O
CC	O
+	O
R.	O
Median	O
follow	O
-	I:C1522577
up	I:C1522577
was	O
46	O
months	O
.	O

A	O
total	O
of	O
268	O
patients	O
were	O
randomized	O
to	O
2	O
courses	O
of	O
melphalan	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
ASCT	O
(	O
MEL	O
200	O
-	O
ASCT	O
)	O
and	O
261	O
to	O
CC	B:C3665472
+	O
R.	O
Median	O
follow	O
-	I:C1522577
up	I:C1522577
was	O
46	O
months	O
.	O

A	O
total	O
of	O
268	O
patients	O
were	O
randomized	O
to	O
2	O
courses	O
of	O
melphalan	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
ASCT	O
(	O
MEL	O
200	O
-	O
ASCT	O
)	O
and	O
261	O
to	O
CC	O
+	O
R.	B:C1144149
Median	O
follow	O
-	I:C1522577
up	I:C1522577
was	O
46	O
months	O
.	O

A	O
total	O
of	O
268	O
patients	O
were	O
randomized	O
to	O
2	O
courses	O
of	O
melphalan	O
200	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
ASCT	O
(	O
MEL	O
200	O
-	O
ASCT	O
)	O
and	O
261	O
to	O
CC	O
+	O
R.	O
Median	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
was	O
46	O
months	O
.	O

MEL	B:C0025241
200-	O
ASCT	O
significantly	O
improved	O
PFS1	O
(	O
median	O
:	O
42	O
vs	O
24	O
months	O
,	O
HR	O
0.53	O
;	O
P	O
<	O
0.001	O
)	O
,	O
PFS2	O
(	O
4	O
years	O
:	O
71	O
vs	O
54	O
%	O
,	O
HR	O
0.53	O
,	O
P	O
<	O
0.001	O
)	O
and	O
OS	O
(	O
4	O
years	O
:	O
84	O
vs	O
70	O
%	O
,	O
HR	O
0.51	O
,	O
P	O
<	O
0.001	O
)	O
compared	O
with	O
CC	O
+	O
R	O
.	O

MEL	O
200-	O
ASCT	B:C0040736
significantly	O
improved	O
PFS1	O
(	O
median	O
:	O
42	O
vs	O
24	O
months	O
,	O
HR	O
0.53	O
;	O
P	O
<	O
0.001	O
)	O
,	O
PFS2	O
(	O
4	O
years	O
:	O
71	O
vs	O
54	O
%	O
,	O
HR	O
0.53	O
,	O
P	O
<	O
0.001	O
)	O
and	O
OS	O
(	O
4	O
years	O
:	O
84	O
vs	O
70	O
%	O
,	O
HR	O
0.51	O
,	O
P	O
<	O
0.001	O
)	O
compared	O
with	O
CC	O
+	O
R	O
.	O

MEL	O
200-	O
ASCT	O
significantly	O
improved	O
PFS1	O
(	O
median	O
:	O
42	O
vs	O
24	O
months	O
,	O
HR	O
0.53	O
;	O
P	O
<	O
0.001	O
)	O
,	O
PFS2	O
(	O
4	O
years	O
:	O
71	O
vs	O
54	O
%	O
,	O
HR	O
0.53	O
,	O
P	O
<	O
0.001	O
)	O
and	O
OS	O
(	O
4	O
years	O
:	O
84	O
vs	O
70	O
%	O
,	O
HR	O
0.51	O
,	O
P	O
<	O
0.001	O
)	O
compared	O
with	O
CC	B:C3665472
+	O
R	O
.	O

MEL	O
200-	O
ASCT	O
significantly	O
improved	O
PFS1	O
(	O
median	O
:	O
42	O
vs	O
24	O
months	O
,	O
HR	O
0.53	O
;	O
P	O
<	O
0.001	O
)	O
,	O
PFS2	O
(	O
4	O
years	O
:	O
71	O
vs	O
54	O
%	O
,	O
HR	O
0.53	O
,	O
P	O
<	O
0.001	O
)	O
and	O
OS	O
(	O
4	O
years	O
:	O
84	O
vs	O
70	O
%	O
,	O
HR	O
0.51	O
,	O
P	O
<	O
0.001	O
)	O
compared	O
with	O
CC	O
+	O
R	B:C1144149
.	O

The	O
advantage	O
was	O
noticed	O
in	O
good	O
and	O
bad	O
prognosis	B:C0033325
patients	O
.	O

Only	O
53	O
%	O
of	O
patients	O
relapsing	O
from	O
CC	B:C3665472
+	O
R	O
received	O
ASCT	O
at	O
first	O
relapse	O
.	O

Only	O
53	O
%	O
of	O
patients	O
relapsing	O
from	O
CC	O
+	O
R	B:C1144149
received	O
ASCT	O
at	O
first	O
relapse	O
.	O

Only	O
53	O
%	O
of	O
patients	O
relapsing	O
from	O
CC	O
+	O
R	O
received	O
ASCT	B:C0040736
at	O
first	O
relapse	O
.	O

Upfront	B:C0040736
ASCT	I:C0040736
significantly	O
reduced	O
the	O
risk	O
of	O
death	O
(	O
HR	O
0.51	O
;	O
P=0.007	O
)	O
in	O
comparison	O
with	O
salvage	O
ASCT	O
.	O

Upfront	O
ASCT	I:C0040736
significantly	O
reduced	O
the	O
risk	O
of	O
death	B:C0011065
(	O
HR	O
0.51	O
;	O
P=0.007	O
)	O
in	O
comparison	O
with	O
salvage	O
ASCT	O
.	O

Upfront	O
ASCT	I:C0040736
significantly	O
reduced	O
the	O
risk	O
of	O
death	O
(	O
HR	O
0.51	O
;	O
P=0.007	O
)	O
in	O
comparison	O
with	O
salvage	B:C0085405
ASCT	O
.	O

Upfront	O
ASCT	I:C0040736
significantly	O
reduced	O
the	O
risk	O
of	O
death	O
(	O
HR	O
0.51	O
;	O
P=0.007	O
)	O
in	O
comparison	O
with	O
salvage	O
ASCT	B:C0040736
.	O

In	O
conclusion	O
,	O
these	O
data	O
confirm	O
the	O
role	O
of	O
upfront	B:C0040736
ASCT	I:C0040736
as	O
the	O
standard	O
approach	I:C0449445
for	O
all	O
young	O
myeloma	O
patients	O
.	O

In	O
conclusion	O
,	O
these	O
data	O
confirm	O
the	O
role	O
of	O
upfront	O
ASCT	I:C0040736
as	O
the	O
standard	B:C0449445
approach	I:C0449445
for	O
all	O
young	O
myeloma	O
patients	O
.	O

In	O
conclusion	O
,	O
these	O
data	O
confirm	O
the	O
role	O
of	O
upfront	O
ASCT	I:C0040736
as	O
the	O
standard	O
approach	I:C0449445
for	O
all	O
young	O
myeloma	B:C0026764
patients	O
.	O

